Uranium Resources, Inc. 

(Public, NASDAQ:URRE)   Watch this stock   
Find more results for URRE

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -179.46% -142.90%
Operating margin -181.52% -145.53%
EBITD margin - -105.88%
Return on average assets -27.17% -55.14%
Return on average equity -37.23% -71.18%
Employees 121 -

Address

650 S. Edmonds Lane, Suite 108
Lewisville, TX 75067
United States - Map
+1-972-2193330 (Phone)
+1-972-2193311 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Uranium Resources, Inc. discussions

  View all discussions »

Description

Uranium Resources, Inc. (URI) is primarily engaged in the business of acquiring, exploring, developing and mining uranium properties using the in situ recovery (ISR) or solution mining process. As of December 31, 2008, the Company owns both producing and undeveloped uranium properties in South Texas and undeveloped uranium properties in New Mexico. In June 2008, the Company and Billiton Investment 15 B.V. agreed to terminate an agreement under which URI agreed to purchase Rio Algom Mining LLC.

Officers and directors

Paul K. Willmott
Executive Chairman of the Board
Age: 69
Bio & Compensation - Reuters
Donald C. Ewigleben
President, Chief Executive Officer, Chief Operating Officer, Director
Age: 53
Bio & Compensation - Reuters
Thomas H. Ehrlich
Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 49
Bio & Compensation - Reuters
Richard A. Van Horn
Chief Operating Officer, Senior Vice President - Operations
Age: 61
Bio & Compensation - Reuters
Mark S. Pelizza
Senior Vice President - Health, Safety and Environmental Affairs
Age: 55
Bio & Compensation - Reuters
Leland O. Erdahl
Director
Age: 80
Bio & Compensation - Reuters
Terence J. Cryan
Director
Age: 46
Bio & Compensation - Reuters
Marvin K. Kaiser
Director
Age: 67
Bio & Compensation - Reuters
Robert Gallagher
Director
Bio & Compensation - Reuters